Cara Therapeutics (CARA) Competitors $0.42 +0.01 (+3.35%) (As of 12/20/2024 05:51 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends CARA vs. ALTS, IMRX, STTK, ALVR, ITRM, IOBT, CELU, CASI, KZR, and VTVTShould you be buying Cara Therapeutics stock or one of its competitors? The main competitors of Cara Therapeutics include Janone (ALTS), Immuneering (IMRX), Shattuck Labs (STTK), AlloVir (ALVR), Iterum Therapeutics (ITRM), IO Biotech (IOBT), Celularity (CELU), CASI Pharmaceuticals (CASI), Kezar Life Sciences (KZR), and vTv Therapeutics (VTVT). These companies are all part of the "pharmaceutical products" industry. Cara Therapeutics vs. Janone Immuneering Shattuck Labs AlloVir Iterum Therapeutics IO Biotech Celularity CASI Pharmaceuticals Kezar Life Sciences vTv Therapeutics Janone (NASDAQ:ALTS) and Cara Therapeutics (NASDAQ:CARA) are both small-cap finance companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, media sentiment, community ranking, valuation, institutional ownership, earnings, profitability, risk and analyst recommendations. Which has more volatility and risk, ALTS or CARA? Janone has a beta of 2.07, meaning that its stock price is 107% more volatile than the S&P 500. Comparatively, Cara Therapeutics has a beta of 0.64, meaning that its stock price is 36% less volatile than the S&P 500. Do analysts prefer ALTS or CARA? Cara Therapeutics has a consensus price target of $2.32, indicating a potential upside of 448.98%. Given Cara Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Cara Therapeutics is more favorable than Janone.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Janone 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Cara Therapeutics 0 Sell rating(s) 5 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Do institutionals and insiders hold more shares of ALTS or CARA? 6.3% of Janone shares are owned by institutional investors. Comparatively, 44.7% of Cara Therapeutics shares are owned by institutional investors. 4.9% of Janone shares are owned by company insiders. Comparatively, 3.1% of Cara Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Does the media favor ALTS or CARA? In the previous week, Cara Therapeutics had 8 more articles in the media than Janone. MarketBeat recorded 8 mentions for Cara Therapeutics and 0 mentions for Janone. Cara Therapeutics' average media sentiment score of 0.31 beat Janone's score of 0.00 indicating that Cara Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Janone Neutral Cara Therapeutics Neutral Which has better earnings and valuation, ALTS or CARA? Janone has higher earnings, but lower revenue than Cara Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioJanone$7.11M7.60-$7.81MN/AN/ACara Therapeutics$8.69M2.67-$118.51M-$1.75-0.24 Is ALTS or CARA more profitable? Janone has a net margin of 0.00% compared to Cara Therapeutics' net margin of -1,099.76%. Cara Therapeutics' return on equity of -367.97% beat Janone's return on equity.Company Net Margins Return on Equity Return on Assets JanoneN/A -2,940.01% -39.81% Cara Therapeutics -1,099.76%-367.97%-107.43% Does the MarketBeat Community believe in ALTS or CARA? Cara Therapeutics received 667 more outperform votes than Janone when rated by MarketBeat users. CompanyUnderperformOutperformJanoneN/AN/ACara TherapeuticsOutperform Votes66772.74% Underperform Votes25027.26% SummaryCara Therapeutics beats Janone on 8 of the 14 factors compared between the two stocks. Ad Crypto Swap ProfitsURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life-changing for those who are prepared. Why? Because altcoin prices are about to explode.>> Register for the Workshop Now Get Cara Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CARA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CARA vs. The Competition Export to ExcelMetricCara TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$23.18M$6.57B$5.10B$9.08BDividend YieldN/A2.97%4.90%4.21%P/E Ratio-0.2410.5090.8717.14Price / Sales2.67195.381,112.67116.85Price / CashN/A57.1642.1437.88Price / Book0.405.104.784.78Net Income-$118.51M$151.51M$119.77M$225.60M7 Day Performance61.30%-2.12%-1.87%-1.23%1 Month Performance36.32%-3.11%11.46%3.07%1 Year Performance-29.05%11.52%30.49%16.48% Cara Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CARACara Therapeutics4.2236 of 5 stars$0.42+3.4%$2.32+449.0%-30.3%$23.18M$8.69M-0.2455News CoverageGap DownHigh Trading VolumeALTSJanoneN/A$3.84-2.0%N/AN/A$54.03M$7.11M0.00170Gap UpIMRXImmuneering3.2169 of 5 stars$1.72+5.2%$12.80+644.3%-70.1%$53.40M$320,000.00-0.8360News CoverageSTTKShattuck Labs2.6767 of 5 stars$1.11-3.1%$8.67+684.3%-82.2%$52.75M$1.66M-0.75100Positive NewsALVRAlloVir0.7122 of 5 stars$0.45+0.5%N/A-81.8%$52.28MN/A-0.51110News CoverageITRMIterum Therapeutics2.0496 of 5 stars$1.88+4.4%$5.00+166.0%+6.0%$51.73MN/A-0.9410IOBTIO Biotech3.2828 of 5 stars$0.77-4.9%$9.33+1,112.0%-47.9%$50.74MN/A-0.5930News CoveragePositive NewsCELUCelularityN/A$2.29+3.2%N/A+36.9%$50.35M$48.20M0.00220CASICASI Pharmaceuticals3.089 of 5 stars$3.20+2.9%$6.00+87.5%-59.2%$49.48M$22.06M-1.39180Positive NewsKZRKezar Life Sciences3.6926 of 5 stars$6.72-0.4%$40.50+502.7%-25.0%$49.03M$7M-0.5160Analyst ForecastNews CoverageVTVTvTv Therapeutics2.0066 of 5 stars$15.30+1.8%$35.00+128.8%+70.4%$48.81M$2.02M-3.329Gap Up Related Companies and Tools Related Companies Janone Competitors Immuneering Competitors Shattuck Labs Competitors AlloVir Competitors Iterum Therapeutics Competitors IO Biotech Competitors Celularity Competitors CASI Pharmaceuticals Competitors Kezar Life Sciences Competitors vTv Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CARA) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cara Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cara Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CARA Stock Alerts